Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01182675 · ClinicalTrials.gov registry record · Phase 2
Hematopoietic Stem Cell Transplantation (HSCT) for Children With SCID Utilizing Alemtuzumab, Plerixafor & Filgrastim
A Phase 2 study, sponsored by University of California, San Francisco.
- Terminated
- Registry status
- Phase 2
- Development phase
- 7
- Enrollment target
NCT01182675: Clinical Trial Phase 2 study, sponsored by University of California, San Francisco.
NCT01182675 is a Phase 2 study that was terminated before completion, run by University of California, San Francisco. The registered enrollment target is 7 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01182675, a Phase 2 study, was terminated before completion, sponsored by University of California, San Francisco.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 7 participants
- Enrollment target
Study Summary
The goal of this study is to develop a novel approach to hematopoietic stem cell transplantation for children with Severe Combined Immunodeficiency Disease (SCID) that eliminates the use of toxic chemotherapy conditioning and maximizes the likelihood of T and B cell immune reconstitution. Rather than classic chemotherapeutic agents, the investigators will utilize a targeted stem cell mobilizer, plerixafor, in combination with alemtuzumab, a monoclonal antibody. Correlative scientific questions will include: 1) efficacy and characteristics of host stem cell mobilization; and 2) alemtuzumab pharmacokinetics in very young children.
Primary Outcome
Number of participants in whom donor B cells were detected in the patient's blood after HSCT.
Interventions
- DRUG Transplant Conditioning with Mobilization Only
- DRUG Transplant Conditioning with Mobilization and Alemtuzumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2010-08 |
| Est. Completion | 2013-09 |
| Phase | Phase 2 |
Why NCT01182675 stopped before completion
NCT01182675 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 2 interventions - of which Transplant Conditioning with Mobilization Only is the first listed.
NCT01182675 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01182675 about?
NCT01182675 is a clinical study titled "Hematopoietic Stem Cell Transplantation (HSCT) for Children With SCID Utilizing Alemtuzumab, Plerixafor & Filgrastim". The goal of this study is to develop a novel approach to hematopoietic stem cell transplantation for children with Severe Combined Immunodeficiency Disease (SCID) that eliminates the use of toxic chemotherapy conditioning and maximizes the likelihood of T and B cell immune reconstitution. Rather tha...
What is the current status of trial NCT01182675?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 7 participants. The study started on 2010-08. Estimated completion is 2013-09.
What interventions are being tested in trial NCT01182675?
The interventions under investigation include: Transplant Conditioning with Mobilization Only (DRUG), Transplant Conditioning with Mobilization and Alemtuzumab (DRUG).
Who is sponsoring clinical trial NCT01182675?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01182675's enrollment target sits among peer trials
7 1996th of 2000 higher than 5 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia